Key Takeaways
- E-1 holders operating biotech & lab businesses qualify based on US revenue — no green card required
- SBA loans closed to all E-1 holders as of March 2026 — Bankable provides direct capital
- 48-hour decisions, funds in 3–5 business days after approval
- Revenue-based repayment flexes with your monthly business performance
- Up to $5M available for qualified E-1 biotech & lab business owners
E-1 Treaty Trader visa holders who own and operate biotech & lab businesses in the United States face a funding environment that has never been more constrained. Traditional US banks apply citizenship or permanent residency requirements before reviewing any other aspect of an application. The SBA's March 2026 rule change eliminated the primary government-backed lending pathway for E-1 holders entirely. And state-chartered banks often apply their own immigration status policies on top of federal restrictions.
E-1 holders from Japan, South Korea, Germany, Israel, and the UK — nations with advanced biotechnology industries — operate US biotech companies that import research materials, specialty reagents, and laboratory equipment from their treaty countries. This creates a funding paradox: a profitable, growing US biotech & lab business that pays US taxes, employs US workers, and generates verifiable US revenue cannot access the capital its growth requires — not because the business isn't creditworthy, but because its owner holds an E-1 visa rather than a green card.
Bankable resolves this paradox. We evaluate your US biotech & lab business on its revenue, its banking history, and its operational consistency. Your visa status is verified for legal compliance, but it does not determine your creditworthiness in our underwriting model. E-1 holders from Japan, South Korea, Israel, Mexico, Turkey, Germany, Italy, the UK, Colombia, and all other treaty nations are evaluated on identical criteria.
Why E-1 Holders Build Biotech & Lab Businesses
Many E-1 Treaty Traders diversify their US presence beyond their primary trade operation into complementary industries. The biotech & lab industry frequently attracts E-1 entrepreneurs because it generates strong, recurring US revenue that can be clearly separated from the treaty trade business — creating a diversified income base and a second qualifying US business entity. Some E-1 holders transition their primary business activity to biotech & lab operations as their treaty trade volume grows and their US business presence deepens.
Capital Uses for E-1 Biotech & Lab Businesses
- Working Capital: Bridge the gap between revenue cycles, manage payroll, and cover operating expenses during growth phases.
- Equipment and Technology: Acquire the equipment and technology systems your biotech & lab business needs to operate and scale, with asset-backed financing at competitive rates.
- Expansion Capital: Fund second locations, new market entry, or significant capacity additions backed by your existing revenue performance.
- Inventory and Materials: Pre-purchase inventory, raw materials, or supplies when favorable terms are available — or when your supplier relationships require advance payment.
- Hiring and Training: Capitalize on growth opportunities by hiring ahead of demand, with working capital that covers payroll until new revenue is fully realized.
- Marketing and Customer Acquisition: Fund advertising, digital marketing, and business development activities that drive the revenue growth your funding facility will be measured against.
How Bankable Works for E-1 Biotech & Lab Operators
The Bankable process starts with your Bankability Score — a 5-minute assessment of your business financial profile that produces a preliminary funding range before you submit any documents. Once you proceed with a full application, you provide 6 months of business bank statements and basic business information. Our underwriting team reviews and issues a decision within 48 hours. Funded businesses typically receive capital within 3–5 business days of approval.
Repayment is structured as a fixed percentage of monthly revenue — when your biotech & lab business has a strong month, payments are larger; slower periods see smaller payments. This structure eliminates the fixed payment stress that causes cash flow problems for growth-stage businesses operating on non-linear revenue curves.
Bankable vs. Traditional Banks for E-1 Biotech & Lab Operators
| Factor | Traditional Bank | Bankable |
|---|---|---|
| Green Card Required | Yes (most) | No |
| Decision Timeline | 30–90 days | 48 hours |
| SBA Access in 2026 | Excluded for E-1 | Direct alternative |
| Collateral Required | Real estate often required | Revenue-based, no property lien |
| Max Amount | Varies, typically lower | Up to $5M |
Related Funding Options
Medical Devices Funding
Explore related capital options for E-1 treaty traders in adjacent business categories.
Explore →Working Capital Line
Revolving credit for operating expenses — draw when needed, repay as revenue arrives.
Explore →Healthcare Practice Funding
Additional E-1 funding options for treaty trader business owners.
Explore →Frequently Asked Questions
Yes. E-1 Treaty Trader visa holders can own and operate biotech & lab businesses in the US. E-1 holders from Japan, South Korea, Germany, Israel, and the UK — nations with advanced biotechnology industries — operate US biotech companies that import research materials, specialty reagents, and laboratory equipment from their treaty countries. Bankable evaluates your US business revenue — not your visa status — to determine funding eligibility.
Bankable requires $20,000 or more in average monthly US business revenue for the trailing 6 months. Revenue deposited in a US business bank account — whether from clients, customers, or contracts — qualifies fully.
The SBA's March 2026 rule change requires US citizenship or national status for all borrowers. Every E-1 visa holder is now excluded from SBA 7(a), SBA 504, and SBA microloans regardless of business performance. Bankable provides equivalent capital without citizenship requirements.
Most E-1 business owners with 6 months of US bank statements receive a decision within 48 hours. Clean financials with consistent monthly deposits often qualify for same-day pre-approval.
Bankable funds E-1 business owners from $25,000 to $5,000,000 based on monthly revenue. Most businesses qualify for 1–3x their average monthly revenue as a starting facility.
Six months of business bank statements, E-1 visa documentation, US business entity registration, and basic revenue information. No tax returns required for initial approval.
Revenue-based funding and working capital lines require no real estate collateral. Equipment financing uses the purchased asset as collateral. No personal real estate lien is required for most facilities under $500K.
Yes. Expansion capital — including second location buildout, equipment, deposits, and working capital — is one of the most common uses for E-1 Bankable funding. Established businesses with proven revenue history qualify for larger expansion facilities.